NCT04139057View on ClinicalTrials.gov

EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

EBV-specific TCR-T cell with anti-PD1 auto-secreted element

Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with anti-PD1 auto-secreted element

Trial Locations (1)

400037

RECRUITING

Department of Oncology, Xinqiao Hospital, Chongqing

All Listed Sponsors
collaborator

TCRCure Biopharma Ltd.

INDUSTRY

lead

Xinqiao Hospital of Chongqing

OTHER